Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change disclosed is a reduction in the shareholding of a senior executive:
- Individual: Mr. W C Louv (Person Discharging Managerial Responsibility)
- Transaction Date: March 22, 2013
- Activity: Sale of 16,000 ADSs
- Price: $46.44 per ADS
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the PDMR transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total remaining holdings of Mr. W C Louv following the sale of 16,000 ADSs.
- Confirm the market price of GSK ADSs on March 22, 2013, to contextualize the $46.44 transaction price.
- Review the company's most recent Form 20-F or quarterly earnings release for actual financial performance metrics, as they are absent from this filing.